Search results
Results from the WOW.Com Content Network
As of 2018, J&J committed to working with the Indian government to support all Indian ASR patients. In late 2018, an Indian government report, the accuracy of which has been disputed by J&J, proposed that each patient who had a faulty implant should receive a lump sum payment of ₹2 million ( US$27,812 ).
6.3 2010 hip-replacement recall. 6.4 2010 Tylenol ... (J&J) is an American ... In September of the same year Johnson & Johnson Medical GmbH acquired Emerging Implant ...
At 120,000 square feet (11,000 m 2), this facility occupies a fraction of the J&J campus, which encompasses 69 acres (280,000 m 2) in total. Manufacturing at JJM began in February 2008. On August 24, 2010, DePuy recalled [4] all ASR hip implant systems sold since 2003.
The U.S. health regulator said it had received reports of pediatric and adult patients suffering burn injuries when the tools, sold under the brand names MEGA 2000 and MEGA SOFT Reusable Patient ...
The affected batches were sold in South Africa, Eswatini, Rwanda, Kenya, Tanzania and Nigeria, the statement added. The recall follows a report by the regulator's Nigerian counterpart on Wednesday ...
Stryker Corporation is an American multinational medical technologies corporation based in Kalamazoo, Michigan. [2] Stryker's products include implants used in joint replacement and trauma surgeries; surgical equipment and surgical navigation systems; endoscopic and communications systems; patient handling and emergency medical equipment; neurosurgical, neurovascular and spinal devices; as ...
This article needs to be updated.The reason given is: the section related to E.U. needs further updates (esp. in sections 3.2 and 4.2.2) as the directives 93/42/EEC on medical devices and 90/385/EEC on active implantable medical devices have been fully repealed on 26 May 2021 by Regulation (EU) no. 2017/745 (MDR); furthermore, Brexit triggers updates in these sections (U.K. developed their own ...
The 29,800-square-foot facility features laboratories for blood, optical, software, mechanical and electrical research, plus a production line. [19] In 2019, Barron's ranked Abiomed the fourth best stock of the 2010s, with total return of 1,983%. [20] while Fortune ranked Abiomed 19th on the magazine's list of 100 fastest-growing companies. [21]